Schneiderman Daniel H 4

4 · Pasithea Therapeutics Corp. · Filed May 5, 2026

AI-generated summary of this filing

Updated May 5, 2026

Pasithea (KTTA) CFO Daniel Schneiderman Receives Option Award

What Happened

Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics (KTTA), was granted an option award covering 1,129,323 shares on May 1, 2026. The Form 4 reports the derivative acquisition price as $0.00. This is an equity compensation grant (award), not an open-market purchase or sale.

Key Details

Transaction date: 2026-05-01 (reported on Form 4 filed 2026-05-05).
Transaction type/code: Grant/Award (derivative) — 1,129,323 shares; reported acquisition price $0.00.
Shares owned after transaction: Not specified in the filing.
Filing timeliness: Filed 2026-05-05 for a 2026-05-01 grant — appears timely.
Footnote highlights: Award governed by the Issuer’s 2023 Stock Incentive Plan; vests 33% after one year, then in equal quarterly installments over the next two years; full vesting upon a Change in Control; vested/exercisable shares may be exercised up to three years after termination of service except for termination for Cause.

Context

This is a compensation grant (an option award). The grant itself does not represent an immediate cash purchase or sale of stock — value is realized only if and when options vest and are exercised (and possibly sold). Such grants are common for executives; purchases or insider sales can be more directly informative about personal conviction. Watch for future Form 4s reporting vesting, exercises, or sales related to this award.

Form 4

Period: 2026-05-01

Chief Financial Officer

Transactions

Award
Stock Option (right to buy)
[F1]
2026-05-01+1,129,323→ 1,129,323 total
Exercise: $0.84Exp: 2036-04-30→ Common Stock (1,129,323 underlying)

Footnotes (1)

[F1]The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan).

Signature

/s/ Daniel Schneiderman|2026-05-05

1 file